José Luís Montero Álvarez

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, José Luís Montero Álvarez et al. · Annals of Oncology · 2018 · 20 citations · Full text

Medicine, Oncology, Pharmacology +14

Prevalence and Predictors of Metabolic Syndrome After Liver Transplantation

Lorena Pérez, José Luís Montero Álvarez, Antonio Poyato González et al. · Transplantation Proceedings · 2016 · 18 citations

Medicine, Internal Medicine, Surgery +14

CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, José Luís Montero Álvarez et al. · Annals of Oncology · 2018 · 17 citations

Medicine, Oncology, Pharmacology +14

Biliary Complications After Liver Transplantation Using Side-to-Side Choledochocholedochostomy Reconstruction With or Without T-Tube

J.M. Benítez Cantero, G. Costán Rodero, José Luís Montero Álvarez et al. · Transplantation Proceedings · 2012 · 12 citations

Medicine, Surgery, Hepatology +10